Skip to content
Dr. Antonio Calles 🫁🚭· @Tony_Calles · X·· 6 hours agoScore70
Body

💥 Ivonescimab, bi-specific PD-1/VEGF, hits a 4th positive Phase III randomized clinical trial, first outside lung cancer indications already approved in China.
✅ 1 L Biliary-tract carcinoma: Ivo + chemo >> Durva + chemo, better ORR, PFS, and OS
#ESMO26

7 views · 0 likes · 0 reposts · 0 replies

Source: Dr. Antonio Calles 🫁🚭 · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.